WO2013058627A3 - 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 - Google Patents
레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 Download PDFInfo
- Publication number
- WO2013058627A3 WO2013058627A3 PCT/KR2012/008674 KR2012008674W WO2013058627A3 WO 2013058627 A3 WO2013058627 A3 WO 2013058627A3 KR 2012008674 W KR2012008674 W KR 2012008674W WO 2013058627 A3 WO2013058627 A3 WO 2013058627A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- rebamipide
- obesity
- compound
- cells
- preventing
- Prior art date
Links
- 229950004535 rebamipide Drugs 0.000 title abstract 6
- 208000008589 Obesity Diseases 0.000 title abstract 5
- 235000020824 obesity Nutrition 0.000 title abstract 5
- ALLWOAVDORUJLA-UHFFFAOYSA-N Rebamipida Chemical compound C=1C(=O)NC2=CC=CC=C2C=1CC(C(=O)O)NC(=O)C1=CC=C(Cl)C=C1 ALLWOAVDORUJLA-UHFFFAOYSA-N 0.000 title abstract 2
- 239000004480 active ingredient Substances 0.000 title 1
- -1 rebamipide compound Chemical class 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 235000013376 functional food Nutrition 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 210000000068 Th17 cell Anatomy 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 210000001789 adipocyte Anatomy 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 231100000433 cytotoxic Toxicity 0.000 abstract 1
- 230000001472 cytotoxic effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 230000003832 immune regulation Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000010172 mouse model Methods 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000003289 regulatory T cell Anatomy 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Food Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
본 발명은 비만을 예방 또는 치료할 수 있는 레바미피드의 신규한 용도에 관한 것으로서, 보다 구체적으로 본 발명은 레바미피드 화합물 또는 그의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 비만의 예방 또는 치료용 약학적 조성물 및 건강 기능성 식품에 관한 것이다. 본 발명에 따른 레바미피드 화합물은 비만이 유도된 마우스 모델에 투여하였을 경우, 투여하지 않은 대조군에 비해 체중 감소 효과, 지방세포 감소 효과 및 체내 총 콜레스테롤 함량 감소 효과가 우수한 것으로 나타났으며, 더불어 염증성 사이토카인을 생성 및 분비하는 세포 독성 Th17 세포의 분화를 억제하는 효과가 우수하고, 비정상적으로 활성화된 면역세포의 기능을 억제하고 염증 반응을 제어하는 특성을 갖는 면역조절 T 세포(Treg)의 활성을 증진시키는 효과가 우수하다는 사실을 확인함으로써, 비만 또는 면역 조절 이상으로 야기되는 비만을 효과적으로 치료할 수 있는 치료제 및 기능성 식품의 제조에 사용될 수 있는 효과가 있다.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/256,708 US20140336220A1 (en) | 2011-10-21 | 2014-04-18 | Composition for preventing or treating obesity comprising rebamipide |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2011-0107914 | 2011-10-21 | ||
| KR20110107914 | 2011-10-21 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US14/256,708 Continuation-In-Part US20140336220A1 (en) | 2011-10-21 | 2014-04-18 | Composition for preventing or treating obesity comprising rebamipide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2013058627A2 WO2013058627A2 (ko) | 2013-04-25 |
| WO2013058627A3 true WO2013058627A3 (ko) | 2013-07-04 |
Family
ID=48141567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/KR2012/008674 WO2013058627A2 (ko) | 2011-10-21 | 2012-10-22 | 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20140336220A1 (ko) |
| KR (1) | KR101395984B1 (ko) |
| WO (1) | WO2013058627A2 (ko) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20140016848A (ko) * | 2012-07-31 | 2014-02-10 | 가톨릭대학교 산학협력단 | 레바미피드를 유효성분으로 포함하는 고지혈증 및 이와 관련된 질환의 예방 또는 치료용 조성물 |
| KR20240067576A (ko) | 2022-11-09 | 2024-05-17 | 비전세미콘 주식회사 | 반도체 제조용 가압오븐 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0971532A (ja) * | 1995-09-06 | 1997-03-18 | Otsuka Pharmaceut Co Ltd | 発癌抑制剤 |
| KR0180248B1 (ko) * | 1991-06-07 | 1999-03-20 | 오오쓰까 아끼히꼬 | 항당뇨병약품 |
| KR20110021016A (ko) * | 2009-08-25 | 2011-03-04 | 가톨릭대학교 산학협력단 | 레바미피드를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물 |
| KR20110100700A (ko) * | 2010-03-05 | 2011-09-15 | 가톨릭대학교 산학협력단 | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 |
| JP2011184429A (ja) * | 2010-02-10 | 2011-09-22 | Univ Of Tsukuba | 低分子抗酸化剤及び高分子化環状ニトロキシドラジカル化合物を含む組成物 |
-
2012
- 2012-10-16 KR KR1020120114823A patent/KR101395984B1/ko active IP Right Grant
- 2012-10-22 WO PCT/KR2012/008674 patent/WO2013058627A2/ko active Application Filing
-
2014
- 2014-04-18 US US14/256,708 patent/US20140336220A1/en not_active Abandoned
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR0180248B1 (ko) * | 1991-06-07 | 1999-03-20 | 오오쓰까 아끼히꼬 | 항당뇨병약품 |
| JPH0971532A (ja) * | 1995-09-06 | 1997-03-18 | Otsuka Pharmaceut Co Ltd | 発癌抑制剤 |
| KR20110021016A (ko) * | 2009-08-25 | 2011-03-04 | 가톨릭대학교 산학협력단 | 레바미피드를 포함하는 류마티스 관절염 예방 또는 치료용 약학 조성물 |
| JP2011184429A (ja) * | 2010-02-10 | 2011-09-22 | Univ Of Tsukuba | 低分子抗酸化剤及び高分子化環状ニトロキシドラジカル化合物を含む組成物 |
| KR20110100700A (ko) * | 2010-03-05 | 2011-09-15 | 가톨릭대학교 산학협력단 | 유효성분으로서 레바미피드를 함유하는 골관절염 예방 또는 치료용 약학 조성물 |
Non-Patent Citations (1)
| Title |
|---|
| HA, HUNJOO ET AL.: "Effects of Rebamipide in a Model of Experimental Diabetes and on the Synthesis of Transforming Growth Factor-beta and Fibronectin, and Lipid Peroxidation Induced by High Glucose in Cultured Mesangial Cells", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, vol. 281, no. 3, 1997, pages 71457 - 1462 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2013058627A2 (ko) | 2013-04-25 |
| KR20130044155A (ko) | 2013-05-02 |
| US20140336220A1 (en) | 2014-11-13 |
| KR101395984B1 (ko) | 2014-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2491328A (en) | Immediate/delayed drug delivery | |
| UA115139C2 (uk) | Спосіб доставки фармацевтичної композиції, яка містить омепразол й ацетилсаліцилову кислоту, пацієнту | |
| MX2013011908A (es) | Composiciones y usos terapeuticos de inhibidores de cinasa epsilon relacionados con cinasa i-kappa b (ikk) y cinasa 1 de union tank. | |
| GB2491327A (en) | Delayed prolonged drug delivery | |
| WO2011014255A8 (en) | Treatment of crohn's disease with laquinimod | |
| TN2012000566A1 (en) | Dry powder formulation comprising an antimuscarinic drug | |
| MX2021011563A (es) | Derivados de 2,3-dihidro-isoindol-1-ona, como inhibidores de la btk quinasa y composiciones farmaceuticas que los incluyen. | |
| TN2012000428A1 (en) | Bisaryl-bonded aryltriazolones and use thereof | |
| GB2491775A (en) | Pulsatile drug release | |
| WO2012145651A3 (en) | Compounds for the treatment of neuropsychiatric disorders | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| PH12016500746B1 (en) | A novel formulation of meloxicam | |
| EP2490700A4 (en) | EXTERNAL SKIN CARE COMPOSITION COMPRISING SALT AND SUGAR AS ACTIVE INGREDIENTS FOR PREVENTING AND TREATING VAGINOSIS AND USE THEREOF | |
| WO2012162439A3 (en) | Compositions comprising fusidic acid and packages therefor | |
| EP2796450A4 (en) | 6-AMINOPYRIDINE-3-OL DERIVATIVES OR THEIR PHARMACEUTICALLY ACCEPTABLE SALTS, AND PHARMACEUTICAL COMPOSITION CONTAINING THESE DERIVATIVES OR THESE SALTS AS ACTIVE INGREDIENTS FOR THE PREVENTION OR TREATMENT OF ANGIOGENESIS DISEASES | |
| WO2010090494A3 (ko) | 5-벤질아미노살리실산 유도체 또는 이의 염의 의약 용도 | |
| MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
| IN2012DN00763A (ko) | ||
| WO2012112232A8 (en) | METHODS AND COMPOSITIONS FOR TREATING β-THALASSEMIA AND SICKLE CELL DISEASE | |
| NZ754706A (en) | Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus | |
| MY179794A (en) | Compound composition for inhalation used for treating asthma | |
| WO2013100718A3 (ko) | 라저스트로에미아 오바리폴리아 추출물 또는 이의 분획물을 유효성분으로 포함하는 염증성 질환 또는 천식의 예방 또는 치료용 약학적 조성물 | |
| WO2013057592A3 (en) | Treatment of sickle cell disease | |
| WO2018093237A3 (ko) | 포름산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 포함하는 비만 또는 비만으로 야기된 대사증후군의 예방 또는 치료용 조성물 | |
| WO2013058627A3 (ko) | 레바미피드를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12842281 Country of ref document: EP Kind code of ref document: A2 |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 12842281 Country of ref document: EP Kind code of ref document: A2 |